Analysts Predict 11% Upside for Dimensional US Vector Equity ETF (DXUV)

Analysts predict an 11% upside for the Dimensional US Vector Equity ETF (DXUV) based on its underlying holdings, with the ETF currently trading at $57.91 per unit and an average analyst target price of $64.40 per unit. Three of DXUV's underlying holdings with notable upside to their analyst target prices are Mastech Digital Inc (MHH), Escalade, Inc. (ESCA), and Electromed, Inc. (ELMD).

Analysts have predicted an 11% upside for the Dimensional US Vector Equity ETF (DXUV), with the ETF currently trading at $57.91 per unit and an average analyst target price of $64.40 per unit. The ETF, which is managed by Dimensional Fund Advisors LP, aims to invest at least 80% of its net assets in equity securities of U.S. companies [1].

Three of DXUV's underlying holdings are expected to contribute significantly to this potential upside. Mastech Digital Inc (MHH), Escalade, Inc. (ESCA), and Electromed, Inc. (ELMD) are among the notable holdings with notable upside to their analyst target prices.

Mastech Digital Inc (MHH) is a technology services company that offers a range of digital transformation solutions. The company has been performing well, with analysts predicting a significant increase in its stock price. Escalade, Inc. (ESCA) is a luxury vehicle manufacturer that has seen strong demand for its high-end models. Electromed, Inc. (ELMD) is a medical technology company that focuses on developing innovative solutions for various health conditions. The company's pipeline includes promising treatments that modulate lipid-signaling pathways for conditions such as cancer, pain, and neurological disorders [2].

The ETF's performance will be influenced by the overall market conditions and the performance of its underlying holdings. Investors should closely monitor the developments in these companies and the broader market to make informed investment decisions.

References:

[1] https://finance.yahoo.com/quote/DXUV/profile/
[2] https://www.ainvest.com/news/waning-ev-demand-automaker-valuations-strategic-production-cuts-reshape-landscape-2509/
[3] https://www.investing.com/news/company-news/artelo-biosciences-prices-3-million-public-offering-of-common-stock-93CH-4224356